Mednax's Unit MedData To Buy Duet Health For Undisclosed Terms

MEDNAX MD' unit MedData, Inc., disclosed the acquisition of Duet Health, which is engaged in developing of patient engagement software, as well as, mHealth solutions. The terms and conditions of the agreement were not revealed. MEDNAX's unit CEO, Ann Barnes, said that "This is a game changer for our clients. This acquisition immediately gives hospitals and providers access to some of the best tools available and a technology platform that will extend their reach and transform their approach to patient engagement. Coupled with our suite of patient-focused services, including eligibility and enrollment, third party liability, and patient reimbursement, clients have a more complete solution to deal with the growing issue of patient responsibility." For its part Duet Health co-founder and CEO, Jeff Harper, reacted to the development by stating that "Joining MedData provides us the unique opportunity to be introduced to a wider audience and become even more integrated into the healthcare provider workflow. Delivering impactful solutions that improve outcomes, increase patient satisfaction, and ultimately boost productivity and ROI will continue to be our focus – but MedData gives us the ability to better scale development and deliver solutions faster to our clients." Duet Health was established in 2009 providing multi-platform software products that empower hospitals, health systems, and providers to better communicate, as well as, engage with their patient populations. The robust Patient Intelligence Center provides real-time monitoring of every click, transaction, and entry to create more meaningful patient interactions and improve operational effectiveness. On Friday, the stock traded 0.76% higher.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsM&APress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!